Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

IP: Rafael Simó Canonge
Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Patricia Bogdanov Baruj, Andreea Ciudin Mihai, Ferran Casals Riera, Itziar Busquets Saez, Maddalen Zufiaurre Seijo, Enrique Franky Vargas, José Raul Herance Camacho, Ingrid Balcells Ortega, Marco Inzitari
Funding agency: EUROPEAN COMMISSION
Funding: 974782.7
Reference: RECOGNISED_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

"Estudi de la suceptibilitat genètica com a predictor de la pèrdua de pes i la resolució de les comorbiditats associades a l'obesitat després de cirurgía bariàtrica"

IP: Rafael Simó Canonge
Collaborators: Gemma Cuberas Borros
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 32160
Reference: SLT002/16/00497
Duration: 01/01/2017 - 31/12/2019

Grups de recerca en Diabetis i Metabolisme

IP: Rafael Simó Canonge
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 20000
Reference: 2017SGR01144
Duration: 12/04/2019 - 30/09/2021

Administración tópica de agonistas del receptor de GLP-1: una nueva estrategia para el tratamiento de la retinopatía deiabética

IP: Rafael Simó Canonge
Collaborators: Patricia Bogdanov Baruj
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 266200
Reference: SAF2016-77784-R
Duration: 30/12/2016 - 29/12/2019

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

José Luis Peiró Ibáñez

José Luis Peiró Ibáñez

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Héctor Carmona Díez

Héctor Carmona Díez

Research assistant
Clinical Pharmacology
Read more
Laura Costa Comellas

Laura Costa Comellas

Predoctoral researcher
Pediatric Neurology
Read more
Javier Sánchez López

Javier Sánchez López

Research technician
Research Group on Status Epilepticus and Acute Seizures
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.